Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX87 + HLX22
- Development stage
- Unknown
- Lead developer
- Henlius
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
HLX87 + HLX22 is a combination therapy being developed by Shanghai Henlius Biotech for the treatment of HER2-positive breast cancer. The combination consists of HLX22, a novel-epitope recombinant humanized anti-HER2 monoclonal antibody, and HLX87, a HER2-targeted antibody-drug conjugate (ADC). HLX22 binds to subdomain IV of the HER2 extracellular region at an epitope distinct from trastuzumab, which promotes receptor internalization and degradation. HLX87 comprises an anti-HER2 antibody conjugated to a topoisomerase I inhibitor payload via a stable, cleavable linker, delivering cytotoxic activity directly to HER2-expressing cells. This dual-targeting approach is designed to enhance anti-tumor efficacy in patients with HER2-positive recurrent or metastatic breast cancer and is currently being evaluated in Phase 2/3 clinical trials.
- Other names
- HLX87 in combination with HLX22HLX-87 in combination with HLX22HLX 87 in combination with HLX22
02
Targets
TOP1 (DNA Topoisomerase I)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on HLX87 + HLX22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX87 + HLX22.